Novartis, The Broad Institute, and Lund University today announced the completion of a genome-wide map of genetic differences in humans and their relationship to type 2 diabetes and other metabolic disorders. All results of the analysis are being made accessible, free of charge on the internet to scientists around the world (Novartis Media Release, Feb 12, 2007)

The results of this study are available at http://www.broad.mit.edu/diabetes/

Has the increasing complexity of genome-wide studies and other large-scale systems biology datasets reached a threshold that makes the open source option more attractive to the pharma industry?